A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease

Table 3 Spirometry and FOT by MostGraph-01® after using each inhaler

	Gly/Ind	Ume/Vil	Tio/Olo	P value
	Gly/Ind	Ume/Vil	Tio/Olo	Gly/Ind versus Ume/Vil	Gly/Ind versus Tio/Olo	Ume/Vil versus Tio/Olo
Spirometry
IC (L)	2.02 ± 0.54	2.03 ± 0.57	2.04 ± 0.56	0.9939	0.9544	0.9812
FVC (L)	2.87 ± 0.74	2.88 ± 0.72	2.95 ± 0.75	0.9993	0.8137	0.8332
FEV1 (L)	1.52 ± 0.57	1.51 ± 0.56	1.52 ± 0.56	0.9969	0.9999	0.9977
MMF (L/s)	0.64 ± 0.38	0.62 ± 0.36	0.61 ± 0.38	0.9620	0.8849	0.9769
PF (L/s)	4.77 ± 1.92	4.73 ± 1.78	4.76 ± 1.83	0.9891	0.9991	0.9944
V50 (L/s)	0.83 ± 0.52	0.82 ± 0.53	0.80 ± 0.56	0.9908	0.9457	0.9805
V25 (L/s)	0.29 ± 0.15	0.27 ± 0.13	0.26 ± 0.15	0.6932	0.6318	0.9947
V50/V25	2.90 ± 1.11	2.97 ± 1.18	2.97 ± 1.22	0.9279	0.9187	0.9997
FOT (average)
R5 (cmH2O/L/s)	3.35 ± 1.11	3.38 ± 1.11	3.30 ± 1.19	0.9856	0.9568	0.8966
R20 (cmH2O/L/s)	2.58 ± 0.85	2.65 ± 0.85	2.52 ± 0.81	0.8771	0.9049	0.6321
R5–R20 (cmH2O/L/s)	0.78 ± 0.42	0.74 ± 0.40	0.78 ± 0.50	0.8418	0.9997	0.8288
X5 (cmH2O/L/s)	− 1.25 ± 1.12	− 1.25 ± 1.10	− 1.32 ± 1.31	0.9997	0.9413	0.9335
Fres (Hz)	12.75 ± 4.88	12.67 ± 4.88	12.85 ± 5.28	0.9952	0.9923	0.9754
ALX (cmH2O/L)	8.50 ± 10.18	8.44 ± 9.78	9.39 ± 12.39	0.9993	0.8781	0.8611

FOT, forced oscillation technique; IC, inspiratory capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; MMF, maximal mid-expiratory flow; PF, peak expiratory flow; V₅₀, forced expiratory flow at 50% of FVC; V₂₅, forced expiratory flow at 25% of FVC; R5, resistance of respiratory system at 5 Hz; R20, resistance of respiratory system at 20 Hz; X5, reactance of respiratory system at 5 Hz; Fres, resonant frequency; ALX, low-frequency reactance area

ISSN: 1471-2466